Key points are not available for this paper at this time.
Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Fabrice André
Eva Ciruelos
Gábor Rubovszky
New England Journal of Medicine
Massachusetts General Hospital
Inserm
Vanderbilt University
Building similarity graph...
Analyzing shared references across papers
Loading...
André et al. (Wed,) studied this question.
www.synapsesocial.com/papers/699ea8a3d8a7e1a4e1facfe4 — DOI: https://doi.org/10.1056/nejmoa1813904